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Purpose: The analysis was designed to compare dosimetric parameters among 3-D conformal radiotherapy
(3DCRT), intensity-modulated radiotherapy (IMRT) and RapidArc (RA) to identify which can achieve the lowest
risk of radiation-induced liver disease (RILD) for hepatocellular carcinoma (HCC).
Methods: Twenty patients with HCC were enrolled in this study. Dosimetric values for 3DCRT, IMRT, and RA were
calculated for total dose of 50 Gy/25f. The percentage of the normal liver volume receiving >40, >30, >20, >10,
and >5 Gy (V40, V30, V20, V10 and V5) were evaluated to determine liver toxicity. V5, V10, V20, V30 and Dmean of liver were
compared as predicting parameters for RILD. Other parameters included the conformal index (CI), homogeneity index
(HI), and hot spot (V110%) for the planned target volume (PTV) as well as the monitor units (MUs) for plan efficiency,
the mean dose (Dmean) for the organs at risk (OARs) and the maximal dose at 1% volume (D1%) for the spinal cord.
Results: The Dmean of IMRT was higher than 3DCRT (p = 0.045). For V5, there was a significant difference:
RA > IMRT >3DCRT (p <0.05). 3DCRT had a lower V10 and higher V20, V30 values for liver than RA (p <0.05).
RA and IMRT achieved significantly better CI and lower V110% values than 3DCRT (p <0.05). RA had better HI,
lower MUs and shorter delivery time than 3DCRT or IMRT (p <0.05).
Conclusion: For right lobe tumors, RapidArc may have the lowest risk of RILD with the lowest V20 and V30
compared with 3DCRT or IMRT. For diameters of tumors >8 cm in our study, the value of Dmean for 3DCRT
was lower than IMRT or RapidArc. This may indicate that 3DCRT is more suitable for larger tumors.
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Hepatocellular carcinoma (HCC) is the third cause of
cancer related death following lung and stomach cancer
[1]. Resection and liver transplantation are generally
regarded as curative treatments for HCC in the early
stage and have shown effective results [2]. However,
surgical resection accompanies high recurrence rate,
and transplantation cannot be universally applicable.* Correspondence: wangrenben@sina.cn
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unless otherwise stated.Now Radiotherapy technology has evolved remarkably
and plays an important role in the treatment of HCC.
During the past decade, improvement of survival had
been observed from a high increase of radiation dose [3,4].
However, a high radiation dose to the liver would give rise
to acute and late hepatic toxicity. Radiation-induced liver
disease (RILD) is the most severe radiation-induced
complication which may result in hepatic failure and
death. The occurrence of RILD is associated with
Child-Pugh grade, hepatic cirrhosis and the volume of
liver receiving radiotherapy (RT). Cheng et al. [5] showed
that both Child-Pugh Class B and the presence of hepatitis
B virus were associated with the risk of RILD. What istd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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of HCC in Asia and Africa [6]. In Liang et al.’s study [7],
the severity of hepatic cirrhosis was proved to be a unique
independent predictor for RILD. Son et al. [8] suggested
that the total liver volume receiving <18Gy should be
greater than 800 cm3 to reduce the risk of the deterior-
ation of hepatic function. Therefore, the study of predict-
ing parameters for RILD risks and sparing more normal
liver during RT is essential for HCC patients.
Now 3DCRT can irradiate the target volume accurately
while minimizing the dose to normal liver and may offer
a chance of long survival for some HCC patients [9].
With the development of an advanced form of 3DCRT,
intensity-modulated radiotherapy (IMRT) can improve
radiation plan quality by using an inverse planning algo-
rithm to generate complex spatial dose distributions to
conform more closely to the target volume. Recent years,
RapidArc (RA) was developed to improve the time effi-
ciency of dose delivery and produce highly conformal
dose spacial distribution by changing treatment apertures
(defined by dynamic multiple leaf collimators) and a
modulated dose rate [10]. Poon et al. [11] have reported
a significant improvement in sparing OAR and better
conformity using RA compared with IMRT. But others
may not. Kan et al. [12] showed that double-arc RA
plans produced slightly inferior parotid sparing and
dose homogeneity than IMRT. The purpose of this
study was to compare the predicting parameters for
RILD among 3DCRT, IMRT and RA for HCC.
Methods
Patient selection
Patients who underwent RT for primary HCC were reg-
istered and the database was retrospectively reviewed
from January 2010 to March 2013 at Shandong Cancer
Hospital. Eligibility criteria were as follows: (1) All pa-
tients underwent alpha-fetoprotein examination, contrast-
enhanced computed to tomography, and ultrasonography
to confirm the diagnosis. (2) No one had cirrhosis or
portal vein thrombosis; (3) All patients had centrally
located lesions on the right liver lobe; (4) Computed
tomography scanning included whole liver, and bilateral
kidney with a 3-mm slice thickness. (5) The patients
experienced transarterial chemoembolization (TACE)
or not. Informed consent was obtained from all patients,
and the local Ethical Board approved the study protocol
(Shandong tumor prevention and control institute ethics
committee).
Target delineation and planning techniques
The patients were fixed using vacuum casts in a supine
position with both arms raised above their heads. There
was no respiratory control training or other means to
decrease degree of excursion of the liver. We defined thegross tumor volume (GTV) as the volume of primary
tumor evident on contrast-enhanced CT images. The clin-
ical target volume (CTV) was delineated on the basis of
the GTV expanded by 5 mm. The planning target volume
(PTV) was defined as the CTV with a 5-mm radial expan-
sion and a 10-mm craniocaudal expansion to account for
errors caused by the daily setup process and internal organ
motion [13]. The OARs considered were healthy liver
(whole liver minus PTV), kidneys, spinal cord and stom-
ach. The target delineation was performed by the same
experienced oncologist. Three sets of plans were all
designed on the Varian Eclipse version 8.6.23 treatment
planning system which was equipped with a Millennium
multileaf collimator (MLC) (Varian) with 120 leaves. For
3DCRT and IMRT plans, all the gantry angles and radi-
ation fields were confirmed according to the relationship
of the PTVs and OARs to different situations, and the
number of fields varied from 4 to 7. For RA, the plan was
generated using two arcs rotating from 55° to 181° anti-
clockwise and from 181° to 55° clockwise with the dose rate
varied between 0 MU/min and 600 MU/min (upper limit).
A fixed DR of 300 MU/min was selected for IMRT and
3DCRT. All three sets of plans were designed by the same
experienced physicist using 6- or 15-MV photon beams.
Planning objectives and evaluation tools
The total prescribe dose was 50 Gy/25f. The planning ob-
jectives were to cover at least 95% of the PTV with the
90% isodose, to have minimum dose > 90% and maximum
dose <110%. All plans were normalized to the mean dose
of PTV to avoid any bias. For OARs, the tolerated max-
imum dose of spinal cord was 40 Gy. The mean dose of
liver was limited to 30 Gy and V30 <50%. The mean dose
of kidneys were 23 Gy (at least one side) and V20 <20%,
the mean dose of stomach <20 Gy [13,14]. For PTV, Vx%
means the volume receiving ≥ x% of the prescribed dose.
For example, the V95% means the volume receiving at least
95% of the prescribed dose and V110% is used to represent
the hot spot in the PTV. The conformal index (CI) =
Vt,ref/Vt × Vt,ref/Vref,where Vt was the volume of PTV, Vref
was the volume enclosed by the prescription dose line,
and Vt,ref is the volume of PTV within Vref [15]. The target
homogeneity was defined as: HI = D5%/D95% where D5%
and D95% are the minimum doses delivered to 5% and 95%
of the PTV [16,17]. The value of HI and CI range from 0
to 1. The more approximate to 1, the better [18].
For OARs, the parameters included the mean dose,
the maximum dose expressed as D1% and a set of ap-
propriate Vx, and Dy, where Vx means the volume of
the OARs receiving the dose > x Gy. For example, V5 of
liver means the volume of normal liver receiving >5 Gy
and presents low-dose exposure for the normal liver.
D1% of spinal cord presents the maximum dose spinal
cord received.
Table 1 Patient characteristics and tumor parameters














Median (Range) 753.11 (34.54–2125.72)
Mean ± SD 526.89 ± 226.24
Equiv. Sphere Diameter (cm)
Median (Range) 8.0 (4.3–17.0)
Mean ± SD 7.5 ± 1.73
PTV (cm3)
Median 533.87 (107.53–3568.03)
Mean ± SD 775.39 ± 361.98
Abbreviations: HBs-Ag hepatitis B surface-antigen, SD standard deviation, GTV
gross tumor volume, PTV planning target volume.
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http://www.ro-journal.com/content/9/1/48What is more, the number of monitor units (MUs) per
fraction and beam-on time were also analyzed to com-
pare the efficiency of three sets of the plans. The treat-
ment delivery time was defined as the time recorded
between beam-on for the first field and beam-off for the
last field.Table 2 Summary of the dosimetric results for OARs
3DCRT IMRT
Liver Dmean (Gy) 20.57 ± 7.12 22. 34 ± 7.33
Liver V5 (%) 68.9 ± 19.23 70.43 ± 18.92
Liver V10 (%) 60.37 ± 21.54 65.12 ± 21.62
Liver V20 (%) 48. 34 ± 21.13 47.73 ±22.81
Liver V30 (%) 22.27 ±17..30 22.57 ± 15.73
Liver V40 (%) 27.73 ± 18.73 17.94 ±10.13
Stomach Dmean (Gy) 14.3 ± 13.93 14.36 ±10.13
Left kidney Dmean (Gy) 2.03 ± 2.45 2.13 ±2.98
Right kidney Dmean (Gy) 6.73 ±8.96 5.13 ± 6.73
Spinal cord D1% (Gy) 20.20 ± 8.34 19.23 ± 9.70
Statistical significance (p <0.05) was reported between couples from paired t-test a
modulated radiation therapy, RA RapidArc. Vx the volume of the OARs receiving the
volume for the organ. a, IMRT versus 3DCRT; b, IMRT versus RA; c, RA versus 3DCRTStatistics analysis
The statistical significance of difference in the outcome
between the three techniques was evaluated using Paired
t-test. All statistical tests were two-tailed and the software
performed for assessment was SPSS 13.0 for Windows




The characteristics of patients are summarized in Table 1.
There were 16 males and 4 females, and their median age
was 60 years (range, 41–65 years). The PTV was 775.39 ±
361.98 (range, 107.53-3568.03 cm3). We divided our
patients into two groups according to the median value
(D = 8 cm) of the tumor diameter. There was no whole
liver included into the PTVs. Table 2 showed the re-
sults with the mean value ± standard deviation for the
considered parameters of OARs. Table 3 showed the
parameters of dose-volume histograms (DVHs) with
the mean value ± standard deviation for PTV, MU and
delivery time. Table 4 showed the predictive parameters
for RILD with the mean value ± standard deviation of
three techniques for larger (D > 8 cm) and smaller
(D ≤ 8 cm) tumors of our study. Figures 1 and 2 showed
the dose distributions of two examples for axial, sagittal,
and coronal views for smaller and larger tumors. Figures 3
and 4 showed DVHs of the PTVs and healthy liver
compared among the three plans for the patients corre-
sponding with Figures 1 and 2.
Target coverage, dose homogeneity and conformity
The coverage of PTVs of the three plans were evaluated
by prescribed dose (V100%), HI and CI. All 95% of pre-
scribed dose could cover at least 99% of the PTV without
any significant difference for three plans. The value of CIRA P-value
a b c
20.51 ± 7.12 0.045 0. 051 0.060
76.34 ± 19.12 0.02 0.015 0.007
64.71 ± 21.63 0.274 0.031 0.004
43. 94 ± 20.10 0.34 0.23 0.012
21.93 ±14..30 0.002 0.450 0.013
17.93 ± 10.24 0.012 0.453 0.038
16.13 ±12..34 0.231 0.937 0.073
2.01 ±2.94 0.45 0.270 0.110
4.36 ±6.58 0.134 0.078 0.734
14.23 ± 7.92 0.721 0.210 0.372
nalysis. Abbreviations: 3DCRT 3-D conformal radiation therapy, IMRT intensity-
dose > x Gy. Dmean the mean dose for the organ, D1% the maximal dose at 1%
.
Table 3 Summary of the dosimetric results for PTVs, MUs and delivery time
PTV 3DCRT IMRT RA P-value
a b c
V95% (%) 99.73 ± 0.28 99.25 ± 1.2 99.23 ± 1.21 0.240 0.067 0.65
V100% (%) 80.57 ± 1.23 79.83 ± 4.01 78.56 ±3.50 0.21 0.23 0.52
V110% (%) 9.33 ± 8.58 3.12 ± 3.09 2.12 ±1.56 0.002 0.50 0.008
CI 0.72 ±0.03 0.83 ±0.04 0.84 ±0.05 0.000 0.633 0.000
HI 1.16 ±0.01 1.08 ±0.03 1.09 ± 0.03 0.072 0.623 0.041
MU 250.4 ± 16.20 853.2 ± 299.2 435.5 ± 134.8 0.000 0.007 0.002
Time (min) 0.92 ± 0.05 2.18 ± 1.10 0.75 ±0.13 0.000 0.000 0.332
Statistical significance (p <0.05) is reported between couples from paired t-test analysis. Abbreviations: PTV planned tumor volume, 3DCRT 3-D conformal radiation
therapy, IMRT intensity-modulated radiation therapy, RA RapidArc, Vx% the volume receiving ≥ x% of the prescribed dose, CI conformity index, HI homogeneity
index, MU monitor unit. a, IMRT versus 3DCRT; b, IMRT versus RA; c, RA versus 3DCRT.
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http://www.ro-journal.com/content/9/1/48for 3DCRT (0.72 ± 0.03) was significantly lower than
that of IMRT (0.83 ± 0.04) (p <0.001) or RA (0.84 ± 0.05)
(p <0.001). The V95% and V100% values were 99.73 ± 0.28
and 80.57 ± 1.23 for 3DCRT, 99.25 ± 1.20 and 79.83 ± 4.01
for IMRT, 99.23 ± 1.21 and 78.56 ±3.50 for RA, respect-
ively, and no significant difference was observed. HI for
3DCRT (1.16 ± 0.01) was higher than RA (1.09 ± 0.03)
(p = 0.041). For the hot spot sparing, the mean V110% of
the PTV was significantly higher for 3DCRT (9.33 ± 8.58)
than IMRT (3.31 ± 3.09) (p <0.001) or RA (2.12 ± 1.56)
(p <0.001). In the typical examples in Figures 1 and 2,
RA and IMRT achieved better conformity of the PTV
compared with 3DCRT.
Organs at risk
The mean dose of the normal liver for each plan was
20.57 ± 7.12 Gy for 3DCRT, 22.34 ± 7.33 Gy for IMRT,
and 20.51 ± 7.12 Gy for RA. We could see a higher value
of IMRT compared with 3DCRT (p = 0.045), but no
difference was found between RA and 3DCRT. For the
low-dose region, V5 was significantly highest for RATable 4 Comparison of predicting parameters for RILD betwe
3DCRT IMRT
Dmean D≤ 8 cm 14.65 ± 3.12 14.32 ± 2. 90
D > 8 cm 25.31 ± 2.73 27.49 ± 2. 33
V5 D≤ 8 cm 58.30 ± 18.04 60.20 ± 17.62
D > 8 cm 81.14 ± 14.70 83.72 ± 14.07
V10 D≤ 8 cm 43.21 ± 10.09 42.50 ± 8.26
D > 8 cm 74.55 ± 20.56 78.15 ± 16.48
V20 D≤ 8 cm 26.83 ± 7.35 28.26 ± 6.92
D > 8 cm 73.20 ± 16.10 64.99 ± 17.14
V30 D≤ 8 cm 18.51 ± 5.43 13.77 ± 4.51
D > 8 cm 27.29 ± 11.32 35. 21 ± 3.57
Statistical significance (p <0.05) was reported between couples from paired t-test a
modulated radiation therapy, RA RapidArc. Vx the volume of the OARs receiving the
versus RA; c, RA versus 3DCRT.(76.34 ± 19.12) and the lowest for 3DCRT (68.90 ± 19.23),
and the difference between IMRT and 3DCRT, IMRT and
RA, 3DCRT and RA were respectively 0.02, 0.015 and
0.007. For V10, RA (64.71 ± 21.63) was higher than 3DCRT
(60.37 ± 21.54, p = 0.004), IMRT (65.12 ± 21.62) was higher
than RA (p = 0.031). No significant difference was ob-
served between IMRT and 3DCRT (p = 0.274). For V20,
RA(43.94 ± 20.10) was lower than 3DCRT (48.34 ± 21.13)
(p = 0.012). For V30 and V40, 3DCRT (22.27 ± 17.30 and
27.73 ± 18.73) was higher than IMRT (22.57 ± 15.73 and
17.94 ± 10.13) (p = 0.002 and p = 0.012, respectively) or RA
(21.93 ± 14.30 and 17.93 ± 10.24) (p = 0.013 and p = 0.038,
respectively). In the DVHs in Figures 3 and 4, Right figure
revealed similar homogeneity of the PTV for 3 plans and
3DCRT obtained highest volume of hot spot. In Figure 3,
left figure showed that RA obtained the highest low-dose
distribution in the normal liver compared with 3DCRT
and IMRT. 3DCRT obtained the highest high-dose dis-
tribution in the normal liver compared with IMRT and
RA. In Figure 4, left figure showed that the low-dose
distributions for three techniques were similar. For V20en smaller and larger tumors
RA P-value
a b c
14.30 ± 2.93 0.064 0.094 0.314
27.01 ± 2.18 0.014 0.433 0.026
66.18 ± 20.74 0.136 0.017 0.019
84.82 ± 14.23 0.051 0.226 0.090
47.62 ± 11.55 0.638 0.080 0.084
80.24 ± 17.61 0.359 0.074 0.189
26.08 ± 5.73 0.428 0.057 0.717
61.98 ± 13.34 0.023 0.273 0.022
14.72 ± 3.67 0.34 0.157 0.024
31.17 ± 2.90 0.062 0.262 0.069
nalysis. Abbreviations: 3DCRT 3-D conformal radiation therapy, IMRT intensity-
dose > x Gy. Dmean the mean dose for the organ, a, IMRT versus 3DCRT. b, IMRT
Figure 1 Isodose curves on axial, coronal, and sagittal views for one representative case of larger tumor. A: 3DCRT, B: IMRT and C: RA.
RA achieved better conformality compared with 3DCRT and IMRT.
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RA, but no statistical significance was observed (Table 4).
For Dmean of stomach, bilateral kidneys and the maximum
dose spinal cord received (D1%), there were no significant
differences.Comparison of predicting parameters for RILD between
smaller and larger tumors
For smaller tumors (D ≤ 8 cm), no difference was observed
among three techniques for Dmean,V20, and V30. For V5
and V10, RA (66.18 ± 20.74, 47.62 ± 11.55) was significantly
higher than 3DCRT (58.30 ± 18.04 and 43.21 ± 10.09)
(p = 0.019 and p = 0.017) or IMRT (60.20 ± 17.62 and
42.50 ± 8.26) (p = 0.084 and p = 0.08). For larger tumors
(D > 8 cm), the Dmean of 3DCRT was lower (25.31 ± 2.73)
than IMRT (27.49 ± 2.33) (p = 0.014) or RA (27.01 ± 2.18)
(p = 0.026). For V5, V10, V20, and V30, no difference was
observed among three techniques.Monitor units, and delivery time
The values of MUs were 250.4 ± 16.20 for 3DCRT,
853.2 ± 299.28 for IMRT and 435.5 ± 134.8 for RA with
a significantly higher MUs for IMRT compared with
3DCRT (p <0.001) or RA (p = 0.007). What is more, IMRT
had a much longer delivery time (2.18 ± 1.10 min)Figure 2 Isodose curves on axial, coronal, and sagittal views for one
RA achieved better conformality compared with 3DCRT and IMRT.compared with 3DCRT (0.92 ± 0.05 min) (p <0.001) or
RA (0.75 ± 0.13 min) (p <0.001).
Discussion
Historically, the role of RT in HCC had been always lim-
ited for the risk of RILD. There have been efforts to
identify the risk factors and the predicting parameters in
the literatures that indicate increased risk of RILD after
RT. In the study of Kim et al., V30 was demonstrated as a
significant parameter in patients treated with conventional
fractionated RT [19]. According to Liang et al., V20 was a
significant parameter in patients treated with conformal
radiotherapy therapy [20]. In our study, there was signifi-
cantly higher V30 of liver for 3DCRT compared with RA
(p = 0.013) or IMRT (p = 0.002). For V20, the values of
3DCRT was also higher than RA (p = 0.012). For V40 in
present study, the value was higher for 3DCRT when
compared with the other two plans but no significant
difference was observed. Therefore, these may indicate
that RA was superior to 3DCRT or IMRT at the risk of
RILD in consideration of lower V20 and V30.
For the issue of higher low-dose region, a meta-analysis
[21] showed that larger low-dose volume of V5 on total
lung might contribute to radiation pneumonitis. Kim et al.
[22] reported that the low-dose coverage V5, V10 to the
stomach were associated with the toxicity. But therepresentative case of smaller tumor. A: 3DCRT, B: IMRT and C: RA.
Figure 3 The comparison of DVHs for normal liver in 3DCRT, IMRT and RA for the larger tumor. Right figure: DVHs of PTV. These three
techniques produced similar homogeneity of the PTV and 3DCRT obtained highest volume of hot spot. Left figure: DVHs of normal liver. RA
obtained the highest low-dose distribution in the normal liver compared with 3DCRT and IMRT. However, 3DCRT obtained the highest high-dose
distribution in the normal liver compared with IMRT and RA.
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http://www.ro-journal.com/content/9/1/48potential risk of RILD caused by low-dose irradiation is
unclear. In present study, there was significant difference
for V5 of liver among three techniques. The result was as
follows: RA > IMRT >3DCRT. For V10, the value of RA
was higher than 3DCRT (p = 0.004) while the value of
IMRT was the highest (p < 0.05). These parameters should
not be overlooked and the role of V5 and V10 for RILD
needs to be elucidated in further studies.
There are many studies demonstrating the relationship
between Dmean and RILD. Dawson et al. reported that a
5% and 50% probability of RILD for patients treated in
their analysis were associated with the mean liver dose
of 31 Gy and 43 Gy [23]. Cheng [24] et al. reported that
the mean liver dose of patients with RILD was signifi-
cantly higher than those without (25.04 Gy vs 19.65 Gy,
p = 0.02). In consideration of the influence of PTV size
to the radiation tolerance [7], we divided the patients
into two groups according to median value (8 cm) of the
tumor diameters. For smaller tumors (D ≤ 8 cm), no differ-
ence was observed except for higher V5 of RA comparedFigure 4 The comparison of DVHs for normal liver in 3DCRT, IMRT an
techniques produced similar homogeneity of the PTV and 3DCRT obtained
three techniques produced similar low-dose distributions the liver. 3DCRT o
was observed.with IMRT (p = 0.017) and 3DCRT (p = 0.019). For larger
tumors (D > 8 cm), 3DCRT achieved lower Dmean com-
pared with IMRT (p = 0.014) or RA (p = 0.026). But for V5,
V10, V20 and V30, there were no differences. This may indi-
cate that 3DCRT may be superior to RA or IMRT at the
risk of RILD in consideration of lower Dmean. Therefore,
for larger tumors in our study, 3DCRT may be more suit-
able among three techniques.
Recent years, RA has gained more interest. Many studies
have showed that RA can achieve superior target coverage,
better conformity, shorter treatment time and less MUs
compared with IMRT or 3DCRT [13,14,25]. In present
study, among the three techniques, RA achieved better CI
and lower V110% compared with 3DCRT. The hot spots in
our study were almost located on tumors, so there is not
much influence of hot spot among three plans. Moreover,
RA had lower V20 and V30 (p < 0.05) for liver. For V95%,
V100%, mean dose of the stomach, kidneys and D1% of the
spinal cord, there were no significant differences for three
techniques. What is more, RA achieved the lowest MUsd RA for the smaller tumor. Right figure: DVHs of PTV. These three
highest volume of hot spot. Left figure: DVHs of normal liver. These
btained the highest V20 and V30, whereas no statistical difference
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http://www.ro-journal.com/content/9/1/48and shortest delivery time which is in line with other
reports [13,14,25]. The reduction of total treatment
time may improve patients’ comfort on the couch, reduce
the risk of inter-fraction movements and minimize organ
displacement. But for larger tumors in our study, RA and
IMRT had higher Dmean of liver compared with 3DCRT.
What is more, the treatment of RA was much more
expensive than 3DCRT.
In our study we had only 20 patients enrolled in our
study which is a small sample. What is more, we did not
combine each technique with respiratory gating and this
might result in a proportion of the liver shifting between
the high- and low-dose regions during RT.
Conclusion
In consideration of lower V20, V30, lower MUs and
shorter delivery time, RA may be superior to 3DCRT or
IMRT in terms of risk of RILD for right liver lobe tumors,
but for larger tumors (D > 8 cm), 3DCRT had the lowest
value of Dmean and may be more suitable among three
techniques. More clinical comparison about the predicting
parameters for RILD risks are needed among different
plans and this may be beneficial to HCC patients.
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